Omnicell (NASDAQ:OMCL) Share Price Breaks Above 200 Day Moving Average – Should You Sell?

Omnicell, Inc. (NASDAQ:OMCL)’s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $38.91 and traded as high as $39.63. Omnicell shares last traded at $39.41, with a volume of 850,494 shares traded.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Wells Fargo & Company reduced their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Zacks Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. KeyCorp restated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Finally, Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Performance

The business’s fifty day moving average price is $34.76 and its two-hundred day moving average price is $38.91. The stock has a market capitalization of $1.79 billion, a P/E ratio of 41.05, a P/E/G ratio of 0.97 and a beta of 0.88. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 29th. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16. The business had revenue of $307.85 million for the quarter, compared to the consensus estimate of $304.44 million. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The company’s revenue for the quarter was down .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.51 EPS. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OMCL. Nykredit A S purchased a new stake in shares of Omnicell during the second quarter valued at about $26,000. Versant Capital Management Inc grew its position in shares of Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after buying an additional 294 shares during the last quarter. Fulcrum Asset Management LLP raised its stake in shares of Omnicell by 2,536.4% during the 3rd quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock worth $40,000 after acquiring an additional 1,116 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in shares of Omnicell during the 2nd quarter worth approximately $105,000. Finally, Nisa Investment Advisors LLC raised its stake in shares of Omnicell by 21.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock worth $89,000 after acquiring an additional 469 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.